<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910530</url>
  </required_header>
  <id_info>
    <org_study_id>INCMGA 0012-104</org_study_id>
    <nct_id>NCT03910530</nct_id>
  </id_info>
  <brief_title>A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b Study of INCMGA00012 (PD-1 Inhibitor), INCB001158 (Arginase Inhibitor), and the Combination in Japanese Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Biosciences Japan GK</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability and the pharmacokinetics&#xD;
      (PK) of INCMGA00012 (PD-1 Inhibitor), INCB001158 (Arginase Inhibitor), and the combination in&#xD;
      Japanese participants with advanced solid tumor malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of treatment-emergent adverse events in participants receiving single-agent INCMGA00012</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of treatment-emergent adverse events in participants receiving single-agent INCB001158</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of treatment-emergent adverse events in participants receiving INCB001158 in combination with INCMGA00012</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax of single-agent INCMGA000012</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Maximum observed plasma or serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax of single-agent INCB001158</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Maximum observed plasma or serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of single-agent INCMGA000012</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Time to maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax of single-agent INCB001158</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Time to maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmin of single-agent INCMGA000012</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Minimum observed plasma or serum concentration over the dose interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmin of single-agent INCB001158</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Minimum observed plasma or serum concentration over the dose interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUCt of single-agent INCMGA000012</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUCt of single-agent INCB001158</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: t½ of single-agent INCMGA000012</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Apparent terminal-phase disposition half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: t½ of single-agent INCB001158</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Apparent terminal-phase disposition half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of INCMGA00012 and INCB001158 as a combination treatment</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Maximum observed plasma or serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Tmax of INCMGA00012 and INCB001158 as a combination treatment</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Time to maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of INCMGA00012 and INCB001158 as a combination treatment</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Minimum observed plasma or serum concentration over the dose interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUCt of INCMGA00012 and INCB001158 as a combination treatment</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: t½ of INCMGA00012 and INCB001158 as a combination treatment</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Apparent terminal-phase disposition half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall response rate with single-agent INCMGA00012</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the percentage of participants experiencing a partial response (PR) or complete response (CR) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall response rate with single-agent INCB001158</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the percentage of participants experiencing a PR or CR as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall response rate with INCMGA00012 in combination with INCB001158</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the percentage of participants experiencing a PR or CR as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Disease control rate with single-agent INCMGA00012</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the number of participants maintaining either an overall response rate or stable disease according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Disease control rate with single-agent INCB001158</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the number of participants maintaining either an overall response rate or stable disease according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Disease control rate with INCMGA00012 in combination with INCB001158</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the number of participants maintaining either an overall response rate or stable disease according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Duration of response with single-agent INCMGA00012</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from first observed response until onset of disease progression according to RECIST v1.1 or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Duration of response with single-agent INCB001158</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from first observed response until onset of disease progression according to RECIST v1.1 or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Duration of response with INCMGA00012 in combination with INCB001158</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from first observed response until onset of disease progression according to RECIST v1.1 or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>INCMGA00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent INCMGA00012.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB001158 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent INCB001158.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB001158 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent INCB001158.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCMGA00012 + INCB001158</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of INCMGA00012 and INCB001158.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retifanlimab</intervention_name>
    <description>Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.</description>
    <arm_group_label>INCMGA00012</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB001158</intervention_name>
    <description>Part 1: INCB001158 75 or 100 mg twice daily administered orally.</description>
    <arm_group_label>INCB001158 100 mg</arm_group_label>
    <arm_group_label>INCB001158 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retifanlimab + INCB001158</intervention_name>
    <description>Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .</description>
    <arm_group_label>INCMGA00012 + INCB001158</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is Japanese&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of any locally advanced or&#xD;
             metastatic solid tumors not amenable to local or other curative therapy.&#xD;
&#xD;
          -  Participants with nonevaluable lesions are allowed.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 to 1.&#xD;
&#xD;
          -  Female participants agree to use medically acceptable contraceptive measures, should&#xD;
             not be breastfeeding, and must have a negative pregnancy test before the start of&#xD;
             study drug administration.&#xD;
&#xD;
          -  Female participants of childbearing potential must understand and accept that&#xD;
             pregnancy must be avoided during participation in the study.&#xD;
&#xD;
          -  Male participants should avoid unprotected sex with women of childbearing potential&#xD;
             and refrain from donating sperm during participation the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of anticancer therapy or participation in another interventional clinical&#xD;
             study within 14 days before the first administration of study drug with the following&#xD;
             exceptions: Immunotherapy or biological therapy (eg, monoclonal antibodies) within 21&#xD;
             days the first administration of study drug; 6 weeks for mitomycin-C or nitrosoureas;&#xD;
             7 days for tyrosine kinase inhibitors.&#xD;
&#xD;
          -  Radiotherapy within 14 days of first dose of study treatment with the following&#xD;
             exceptions: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy&#xD;
             that is &gt; 30 Gy.&#xD;
&#xD;
          -  Toxicity of prior therapy and/or complications from surgical intervention that has not&#xD;
             recovered to ≤ Grade 1 or baseline within 7 days before starting study drug treatment&#xD;
             (with the exception of anemia not requiring transfusion support and any grade of&#xD;
             alopecia). Note: Endocrinopathy, if well-managed, is not exclusionary and should be&#xD;
             discussed with sponsor medical monitor.&#xD;
&#xD;
          -  Receipt of prior systemic treatment with an arginase inhibitor&#xD;
&#xD;
          -  Immune-related toxicity during prior checkpoint inhibitor therapy for which permanent&#xD;
             discontinuation of therapy is recommended (per product label or consensus guidelines),&#xD;
             OR any immune-related toxicity requiring intensive or prolonged immunosuppression to&#xD;
             manage (with the exception of endocrinopathy that is well controlled on replacement&#xD;
             hormones).&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic immunosuppression in excess of&#xD;
             physiologic maintenance doses of corticosteroids (&gt; 10 mg of prednisone or&#xD;
             equivalent).&#xD;
&#xD;
          -  Known active central nervous system metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Known active hepatitis A virus, hepatitis B virus, or hepatitis C virus infection.&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Active infections requiring systemic therapy.&#xD;
&#xD;
          -  Known hypersensitivity to another monoclonal antibody that cannot be controlled with&#xD;
             standard measures and/or known hypersensitivity ≥ Grade 3, or severe reaction, to&#xD;
             study treatments or any of their excipients or additives.&#xD;
&#xD;
          -  Participants with impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
          -  Evidence of interstitial lung disease or active, noninfectious pneumonitis or a&#xD;
             history of interstitial lung disease.&#xD;
&#xD;
          -  Participant is pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eiji Ueda, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Biosciences Japan GK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>metastatic solid tumors</keyword>
  <keyword>INCMGA00012</keyword>
  <keyword>INCB001158</keyword>
  <keyword>Japan</keyword>
  <keyword>PD-1 Inhibitor</keyword>
  <keyword>Arginase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

